-
1.发明申请COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY 审中-公开具有肌钙蛋白受体拮抗剂和BETA2 ADRENERGIC受体激动剂的化合物公开(公告)号：US20150139916A1
公开(公告)日：2015-05-21
申请号：US14609524
申请日：2015-01-30
Applicant: CHIESI FARMACEUTICI S.p.A.
Inventor： Fabio RANCATI , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: C07D453/02 , A61K9/00 , A61K45/06 , A61K31/4709 , A61K31/496
CPC classification number: C07D453/02 , A61K9/0073 , A61K31/4709 , A61K31/496 , A61K45/06 , A61M15/0045 , A61M15/009 , A61M16/14
Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
Abstract translation: 本文定义的式（I）化合物既作为毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂，也可用于预防和/或治疗支气管阻塞性或炎性疾病。
-
2.发明授权公开(公告)号：US10196386B2
公开(公告)日：2019-02-05
申请号：US15647901
申请日：2017-07-12
Applicant: CHIESI FARMACEUTICI S.P.A.
Inventor： Fabio Rancati , Andrea Rizzi , Laura Carzaniga , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: C07D409/14 , A61K31/4709 , A61K9/00 , A61K31/497 , A61K31/506 , A61K45/06 , A61M15/00 , A61M16/14 , C07D401/14 , C07D405/14 , C07D417/14 , C07D471/08 , C07D495/04
Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
-
3.发明授权Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity 有权具有毒蕈碱受体拮抗剂和BETA2肾上腺素受体激动剂活性的化合物公开(公告)号：US09579314B2
公开(公告)日：2017-02-28
申请号：US15040382
申请日：2016-02-10
Applicant: CHIESI FARMACEUTICI S.p.A.
Inventor： Fabio Rancati , Andrea Rizzi , Laura Carzaniga , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: C07D453/02 , A61K31/4704 , C07D403/12 , C07D401/14 , A61K31/4709 , C07D401/12 , C07D453/04 , A61K9/00 , A61K31/496 , A61K45/06 , C07D215/227 , C07D409/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D498/10
CPC classification number: A61K31/4709 , A61K9/0073 , A61K31/4704 , A61K31/496 , A61K31/5386 , A61K45/06 , C07D215/227 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/14 , C07D453/02 , C07D453/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D498/10
Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
Abstract translation: 式I定义的化合物既作为毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂，也可用于治疗支气管阻塞性和炎性疾病。
-
4.发明授权公开(公告)号：US10004728B2
公开(公告)日：2018-06-26
申请号：US15404897
申请日：2017-01-12
Applicant: CHIESI FARMACEUTICI S.p.A.
Inventor： Fabio Rancati , Andrea Rizzi , Laura Carzaniga , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: A61K31/4709 , C07D403/12 , C07D401/14 , C07D401/12 , C07D453/02 , C07D453/04 , A61K9/00 , A61K31/4704 , A61K31/496 , A61K45/06 , C07D215/227 , C07D409/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D498/10 , A61K31/5386
CPC classification number: A61K31/4709 , A61K9/0073 , A61K31/4704 , A61K31/496 , A61K31/5386 , A61K45/06 , C07D215/227 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/14 , C07D453/02 , C07D453/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D498/10
Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.
-
Patent Agency Ranking
5.发明授权公开(公告)号：US09453013B2
公开(公告)日：2016-09-27
申请号：US14609524
申请日：2015-01-30
Applicant: CHIESI FARMACEUTICI S.p.A.
Inventor： Fabio Rancati , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: C07D453/02 , A61K31/496 , A61K31/4709 , A61K45/06 , A61M15/00 , A61M16/14 , A61K9/00
CPC classification number: C07D453/02 , A61K9/0073 , A61K31/4709 , A61K31/496 , A61K45/06 , A61M15/0045 , A61M15/009 , A61M16/14
Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
-
6.发明申请公开(公告)号：US20180016267A1
公开(公告)日：2018-01-18
申请号：US15647901
申请日：2017-07-12
Applicant: CHIESI FARMACEUTICI S.P.A.
Inventor： Fabio RANCATI , Andrea Rizzi , Laura Carzaniga , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: C07D409/14 , A61K45/06 , A61M16/14 , A61K31/4709 , A61K9/00 , A61K31/506 , A61K31/497 , C07D401/14 , A61M15/00
CPC classification number: C07D409/14 , A61K9/0073 , A61K31/4709 , A61K31/497 , A61K31/506 , A61K45/06 , A61M15/009 , A61M16/14 , A61M2202/064 , C07D401/14 , C07D405/14 , C07D417/14 , C07D471/08 , C07D495/04
Abstract: Compounds of formula I defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
-
7.发明授权公开(公告)号：US09662323B2
公开(公告)日：2017-05-30
申请号：US15168466
申请日：2016-05-31
Applicant: CHIESI FARMACEUTICI S.p.A.
Inventor： Laura Carzaniga , Fabio Rancati , Andrea Rizzi , Ian Linney , Wolfgang Schmidt , Michael Barnes , Chris Knight
IPC: A61K31/4709 , C07D453/02 , A61K9/00 , A61M15/00 , A61M16/14
CPC classification number: A61K31/4709 , A61K9/0073 , A61M15/009 , A61M16/14 , A61M2202/064 , C07D453/02
Abstract: Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating diseases of the respiratory tract.
-
8.发明授权Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity 有权具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物公开(公告)号：US08980913B2
公开(公告)日：2015-03-17
申请号：US14098662
申请日：2013-12-06
Applicant: Chiesi Farmaceutici S.p.A.
Inventor： Fabio Rancati , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: A61K31/04 , C07D215/38 , A61K31/4709 , A61K45/06 , A61M15/00 , A61M16/14 , C07D453/02
CPC classification number: C07D453/02 , A61K9/0073 , A61K31/4709 , A61K31/496 , A61K45/06 , A61M15/0045 , A61M15/009 , A61M16/14
Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
Abstract translation: 本文定义的式（I）化合物既作为毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂，也可用于预防和/或治疗支气管阻塞性或炎性疾病。
-
9.发明申请COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY 有权具有肌钙蛋白受体拮抗剂和BETA2 ADRENERGIC受体激动剂的化合物公开(公告)号：US20140163066A1
公开(公告)日：2014-06-12
申请号：US14098662
申请日：2013-12-06
Applicant: Chiesi Farmaceutici S.p.A.
Inventor： Fabio RANCATI , Ian Linney , Chris Knight , Wolfgang Schmidt
IPC: A61K31/4709 , A61M16/14 , A61M15/00 , C07D453/02 , A61K45/06
CPC classification number: C07D453/02 , A61K9/0073 , A61K31/4709 , A61K31/496 , A61K45/06 , A61M15/0045 , A61M15/009 , A61M16/14
Abstract: Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases.
Abstract translation: 本文定义的式（I）化合物既作为毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂，也可用于预防和/或治疗支气管阻塞性或炎性疾病。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.026 seconds)
